Show simple item record

dc.contributor.authorUnruh, Dusten
dc.contributor.authorÜnlü, Betü
dc.contributor.authorLewis, Clayton S.
dc.contributor.authorQi, Xiaoyang
dc.contributor.authorChu, Zhengtao
dc.contributor.authorSturm, Robert
dc.contributor.authorKeil, Ryan
dc.contributor.authorAhmad, Syed A.
dc.contributor.authorSovershaev, Timofey
dc.contributor.authorAdam, Mariette
dc.contributor.authorVan Dreden, Patrick
dc.contributor.authorWoodhams, Barry J.
dc.contributor.authorRamchandani, Divya
dc.contributor.authorWeber, Georg F.
dc.contributor.authorRak, Janusz W.
dc.contributor.authorWolberg, Alisa S.
dc.contributor.authorMackman, Nigel
dc.contributor.authorVersteeg, Henri H.
dc.contributor.authorBogdanov, Vladimir Y.
dc.date.accessioned2017-03-14T10:28:19Z
dc.date.available2017-03-14T10:28:19Z
dc.date.issued2016
dc.description.abstractAlternatively spliced Tissue Factor (asTF) is a secreted form of Tissue Factor (TF), the trigger of blood coagulation whose expression levels are heightened in several forms of solid cancer, including pancreatic ductal adenocarcinoma (PDAC). asTF binds to β1 integrins on PDAC cells, whereby it promotes tumor growth, metastatic spread, and monocyte recruitment to the stroma. In this study, we determined if targeting asTF in PDAC would significantly impact tumor progression. We here report that a novel inhibitory anti-asTF monoclonal antibody curtails experimental PDAC progression. Moreover, we show that tumor-derived asTF is able to promote PDAC primary growth and spread during early as well as later stages of the disease. This raises the likelihood that asTF may comprise a viable target in early- and late-stage PDAC. In addition, we show that TF expressed by host cells plays a significant role in PDAC spread. Together, our data demonstrate that targeting asTF in PDAC is a novel strategy to stem PDAC progression and spread.en_US
dc.description.sponsorshipThis works was partially supported by NIH/NCI grants R21CA160293-01A1/R01CA190717-01A0 to V.Y.B., R01CA158372-01A0 to X.Q., and NWO VIDI grant 91710329 to H.H.V.en_US
dc.descriptionPublished version. Source at <a href=http://doi.org/10.18632/oncotarget.7955>http://doi.org/10.18632/oncotarget.7955</a>. License <a href=https://creativecommons.org/licenses/by/3.0/>CC BY 3.0</a>.en_US
dc.identifier.citationUnruh D, Ünlü, Lewis, Qi, Chu, Sturm, Keil, Ahmad, Sovershaev TA, Adam, Van Dreden, Woodhams, Ramchandani, Weber, Rak, Wolberg, Mackman N, Versteeg HH, Bogdanov. Antibody-based targeting of alternatively spliced tissue factor: A new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. OncoTarget. 2016;7(18):25264-25275en_US
dc.identifier.cristinIDFRIDAID 1390023
dc.identifier.doi10.18632/oncotarget.7955
dc.identifier.issn1949-2553
dc.identifier.urihttps://hdl.handle.net/10037/10639
dc.language.isoengen_US
dc.publisherImpact Journalsen_US
dc.relation.journalOncoTarget
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectpancreatic canceren_US
dc.subjecttissue factoren_US
dc.subjectalternative splicingen_US
dc.subjectβ1 integrinsen_US
dc.subjectmetastasisen_US
dc.titleAntibody-based targeting of alternatively spliced tissue factor: A new approach to impede the primary growth and spread of pancreatic ductal adenocarcinomaen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record